Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

upplies

associated with the company's clinical trials and research initiatives,

were $12.6 million, down from $13.9 million in the previous quarter and

up from $7.9 million in the fourth quarter of 2006. The decrease in R&D

expenses between the third and fourth quarters of 2007 is primarily

attributable to an increase in VEC-162 Phase III chronic insomnia

clinical trial costs being offset by a non-recurring third quarter

milestone charge of $5.0 million for the Fiapta(TM) NDA submission in

September 2007. The increase in R&D expenses in the fourth quarter of

2007 relative to the fourth quarter of 2006 is primarily attributable

to the same VEC-162 Phase III chronic insomnia clinical trial that was

initiated in late 2007. For the full year of 2007, total R&D expenses

were $47.2 million, down from $52.1 million in the full year of 2006.

Lower R&D expenses in 2007 resulted from the substantial completion of

the Fiapta(TM) Phase III clinical program in 2006.

General and administrative (G&A) expenses totaled $9.5 million in the

fourth quarter of 2007, down slightly from $9.6 million in the third

quarter of 2007, and up from $4.5 million in the fourth quarter of

2006. The increase in G&A expenses in the fourth quarter of 2007

relative to the fourth quarter of 2006 is primarily due to increased

Fiapta(TM) pre-launch commercial activities, stock-based compensation

charges, salaries and related costs of non-R&D personnel, insurance and

facility expenses. For the full year of 2007, total G&A expenses were

$32.8 million, up from $13.6 million in the prior year. The increase

in G&A expenses is primarily due to increased salaries, benefits and

stock-based compensation expense, increased business and commercial

development expenses, and higher insu
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... SOUTH SAN FRANCISCO, Calif., Aug. 27 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that Jerry McMahon, Ph.D., ... in early September: The Thomas Weisel Partners ... p.m. Eastern time at the Four Seasons Hotel ...
... Aug. 27 Sanofi-aventis,U.S. launched today a new ... (oxaliplatin injection) for patients who have,adjuvant stage III ... to offer more convenience, efficiency and safety in ... had been,available in 50 mg and 100 mg ...
... Diabetes Meta-Database to Quantify Competitive Treatment Landscape and Accelerate ... ... MOUNTAIN VIEW, Calif., Aug. 27 Pharsight,Corporation (OTC Bulletin Board: ... clinical drug development, today,announced that it has licensed its public-source ...
Cached Biology Technology:Poniard Pharmaceuticals Announces Participation in Upcoming Conferences 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 2New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 3New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 4New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 5New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 6New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation 7Pharsight Achieves First License Sale for Public-Source Database 2Pharsight Achieves First License Sale for Public-Source Database 3
(Date:7/10/2014)... teens living with a cardiac pacemaker, a low sense ... life, reports a study in the July ... official journal of the Society for Developmental and ... Lippincott Williams & Wilkins , a part of ... as a protective factor against lower health-related quality of ...
(Date:7/10/2014)... used to control everyday household items such as washing ... for conservation, a new study has claimed., As part ... scientists and mathematicians, including those from the University of ... engineering, could be replicated in the natural world to ... ,integral control, - in essence a built-in feedback control ...
(Date:7/10/2014)... Consuming a whole fresh avocado with either an orange-colored ... carotenoid (alpha- and beta-carotene) absorption and conversion of these ... to new research (1) published in The ... A is involved in reproductive health and growth promotion; ... has antioxidant properties. Provitamin A carotenoids, like alpha- and ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2Feedback control could be key to robust conservation management 2New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2
... Kolls, Professor and Chairman of Genetics at the LSU Health ... a $2.1 million grant over five years by the National ... Health to further his work on a discovery that plays ... Bacterial pneumonia is an important clinical problem and defense mechanisms ...
... a first-of-its-kind cloth that releases nitric oxide gas an ... a wrap to help preserve organs harvested for transplantation. The ... bi-weekly journal. Kenneth Balkus and Harvey Liu note in ... flow and regulates a range of other body functions. Scientists ...
... drugs are embracing new tactics to deal with an ... far from being won. That,s the focus of an ... Engineering News (C&EN) , ACS, weekly newsmagazine. Counterfeiting ploys ... to identify their products as genuine. C&EN Associate ...
Cached Biology News:LSUHSC awarded multi-million dollar grant to reduce pneumonia 2
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
ANTI K. AEROGENES...
Biology Products: